Biocardia announces united states patent issuance on morph dna multi-directional steerable catheter transseptal application

Sunnyvale, calif., july 17, 2024 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the unites states patent office has granted patent no: 12,036,371 titled “method of accessing the left atrium with a multi-directional steerable catheter,” with a patent term that will expire in 2035.
BCDA Ratings Summary
BCDA Quant Ranking